Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
firicabtagene autoleucel (CRG-022) / CARGO Therap
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma	Recruiting	2	123	US	Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)	CARGO Therapeutics	Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)	09/25	12/26
IRB-50836, NCT04088890: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies	Active, not recruiting	1	52	US	Fludarabine, Cyclophosphamide, CD22 CAR	Stanford University, National Cancer Institute (NCI)	B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL, Follicular Lymphoma Grade 3B	12/24	12/37
NCT06408194: Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies	Recruiting	1	20	US	CD22CART infusion, Tisagenlecleucel, KYMRIAH	Stanford University	Leukemia, Acute Lymphoblastic Leukemia	06/25	06/25
NCT04088864: CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies	Active, not recruiting	1	10	US	Fludarabine, Cyclophosphamide, Autologous CD22 CAR T	Stanford University	B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma	10/23	09/36